ARCA biopharma (ABIO) Financials

$7.8 M

Mkt cap, 15-May-2018
Net income (Q1, 2018)-2.7 M
EBIT (Q1, 2018)-2.8 M
Cash, 31-Mar-201812.1 M

Revenue/Financials

Income Statement

Annual

USDFY, 2016FY, 2017

R&D expense

14.1 m

General and administrative expense

4.6 m

Operating expense total

18.7 m

EBIT

(18.7 m)

Interest expense

6 k

Interest income

167 k

Pre tax profit

(18.6 m)

Income tax expense

61 k

Net Income

(16.4 m)(18.5 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

R&D expense

1.4 m1.3 m1.7 m

General and administrative expense

1 m950 k1.1 m

Operating expense total

2.4 m2.3 m2.8 m

EBIT

(2.4 m)(2.3 m)(2.8 m)

Interest expense

3 k

Interest income

41 k

Pre tax profit

(2.4 m)(2.3 m)

Net Income

(4.8 m)(7.1 m)(2.7 m)(5.5 m)(8.3 m)(3.6 m)(7.5 m)(12.2 m)(4.3 m)(2.7 m)

Balance Sheet

Annual

USDFY, 2016FY, 2017

Cash

7.4 m8.7 m

Current Assets

21.4 m12.3 m

PP&E

66 k42 k

Total Assets

24.6 m12.4 m

Accounts Payable

1.2 m622 k

Current Liabilities

2.4 m2.1 m

Total Liabilities

2.4 m2.1 m

Additional Paid-in Capital

134.7 m141.3 m

Retained Earnings

(112.5 m)(131 m)

Total Equity

22.2 m10.3 m

Financial Leverage

1.1 x1.2 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Cash

19.4 m17.2 m12.2 m44.1 m41.5 m29.7 m14.4 m8.1 m6.2 m12.1 m

Current Assets

19.7 m17.5 m12.7 m44.3 m41.7 m31 m26.7 m23.8 m19.9 m12.7 m

PP&E

29 k26 k34 k34 k31 k24 k76 k69 k59 k37 k

Total Assets

20.5 m18 m13.3 m45.1 m42.4 m36.9 m32.6 m28.7 m20.6 m12.8 m

Accounts Payable

725 k365 k651 k714 k647 k744 k760 k1.1 m980 k772 k

Current Liabilities

1.2 m838 k1.1 m1.4 m1.3 m2.3 m1.7 m2.2 m2.5 m1.7 m

Total Liabilities

1.7 m

Additional Paid-in Capital

99 m99.2 m99.5 m133.8 m134 m134.3 m134.5 m134.7 m134.9 m144.8 m

Retained Earnings

(79.7 m)(82 m)(87.4 m)(90.1 m)(92.9 m)(99.7 m)(103.6 m)(108.3 m)(116.8 m)(133.7 m)

Total Equity

43.8 m41.1 m34.6 m30.9 m26.5 m18 m11.1 m

Financial Leverage

1 x1 x1.1 x1.1 x1.1 x1.1 x1.2 x

Cash Flow

Annual

USDFY, 2016FY, 2017

Net Income

(16.4 m)(18.5 m)

Depreciation and Amortization

24 k27 k

Accounts Payable

841 k(583 k)

Cash From Operating Activities

(15 m)(17.5 m)

Purchases of PP&E

(12 k)(3 k)

Cash From Investing Activities

(16.4 m)12.9 m

Cash From Financing Activities

34 m5.8 m

Interest Paid

4 k6 k

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(4.8 m)(7.1 m)(2.7 m)(5.5 m)(8.3 m)(3.6 m)(7.5 m)(12.2 m)(4.3 m)(2.7 m)

Depreciation and Amortization

5 k8 k4 k9 k14 k5 k9 k17 k7 k6 k

Accounts Payable

128 k(232 k)(144 k)(198 k)(167 k)380 k391 k648 k(234 k)(14 k)

Cash From Operating Activities

(5.5 m)(7.5 m)(3.1 m)(5.5 m)(7.9 m)(3.9 m)(7.4 m)(11.1 m)(4.3 m)(3.1 m)

Purchases of PP&E

(5 k)(5 k)(2 k)(7 k)(9 k)(1 k)(2 k)(8 k)(1 k)(1 k)

Cash From Investing Activities

(5 k)(5 k)(2 k)(7 k)(9 k)(5.2 m)(17 m)(19.6 m)3 m3 m

Cash From Financing Activities

8.1 m8 m(55 k)34.3 m34.1 m(55 k)34.3 m34.1 m105 k3.4 m

Interest Paid

2 k3 k1 k3 k4 k1 k3 k4 k

Ratios

USDY, 2018

Financial Leverage

1.2 x
Report incorrect company information